Biotechnology - Pharmacyclics


Current filters:


Popular Filters

Pharmacyclics seeks additional indication for Imbruvica in USA

Pharmacyclics seeks additional indication for Imbruvica in USA


USA-based Pharmacyclics has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug…

BiotechnologyImbruvicaJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmacyclicsRegulationUSA

FDA acceptance of ibrutinib NDA triggers milestone for Pharmacyclics


California, USA-based Pharmacyclics (Nasdaq: PCYC) said yesterday (August 29, 2013) that the US Food…

BiotechnologyibrutinibJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulation

US FDA grants "breakthrough" status for Janssen and Pharmacyclics ibrutinib


US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Research & Development, says that…

BiotechnologyibrutinibJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationResearch

Pharmacyclics gets second $50 million milestone from Janssen


California, USA-based Pharmacyclics (Nasdaq: PCYC) announced yesterday that the SPARK (MCL2001) clinical…

BiotechnologyFinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Highlights of ASH meeting


Among presentations at this year’s Annual Meeting of the American Society of Hematology (ASH), held…

AEterna ZentarisAriad PharmaceuticalsBiotechnologyblinatumomabMicrometOncologyperifosinePharmaceuticalPharmacyclicsponatinibResearch

Back to top